Proma

Quick links to important sections

Proma

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Proma

Property Description
Active ingredient Chlorpromazine, Promazine
Form Tablet, Injectable Solution
Pharmacological class Typical Antipsychotic, Neuroleptic
General purpose Psychological distress, Severe Nausea/Vomiting
Origin Synthetic organic

What is Proma and What Type of Medicine is It?

Proma is a prescription-only combination medicine classified as a neuroleptic, which belongs to the Typical Antipsychotic class, also known as First-Generation Antipsychotics (FGAs). This classification is rooted in the drug's core chemical identity as a phenothiazine derivative. Its status as a combination of two distinct phenothiazines is a differentiating feature, often employed when clinicians require the combined properties of both compounds.

Chlorpromazine is categorized under ATC code N05AA01, which identifies its function as a primary antipsychotic agent. This designation reflects the medicine's long-established therapeutic purpose, which is clinically recognized for its effects on central nervous system processes.


Composition, Origin, and Available Forms

The active constituents of Proma are the synthetic organic compounds Chlorpromazine Hydrochloride and Promazine, establishing it as a combination product. Chlorpromazine is widely recognized as the prototypical phenothiazine antipsychotic compound, while Promazine is a closely allied analogue often preferred in specific sedating contexts. Proma is produced in multiple dosage forms, including the solid tablet form suitable for the oral route of administration and a sterile solution designed for parenteral delivery via injection. This availability in both oral and injectable forms provides clinical flexibility.


General Purpose of Proma

The general purpose of Proma is to stabilize profound psychological distress by exerting effects on neuronal signaling, which serves to alleviate severely disrupted mental states and agitation. This ability to normalize brain chemistry and induce prominent sedative effects is the primary general benefit associated with its Typical Antipsychotic designation. The medication also exhibits a secondary physiological action as an antiemetic, meaning it is used to provide relief from certain cases of severe, persistent nausea and vomiting.

Regulatory References

  1. U.S. Food and Drug Administration

What side effects are possible with Proma?

The official safety characteristics of this medication are primarily related to its neuroleptic classification, involving central nervous system effects, cardiovascular changes, and metabolic disturbances, as documented in government regulatory information.

Adverse Reaction Scope

Key adverse reaction categories: The safety profile is dominated by reactions affecting the Central Nervous System (CNS), Cardiovascular System, and Autonomic Nervous System, with recognized risks for Extrapyramidal Symptoms (EPS) and serious metabolic/hematological events.

Classification Representative Side Effects Affected System-Organ Classes
Very Common (geq1/10) Sedation, Somnolence, Dry mouth, Constipation, Weight increased Nervous System, Gastrointestinal, Metabolism
Common (geq1/100) Orthostatic Hypotension, Hyperprolactinaemia, Anxiety, ECG changes (QT Prolonged) Vascular, Endocrine, Nervous System, Cardiac

Serious Adverse Reactions: Official regulatory documentation details risks for Neuroleptic Malignant Syndrome (NMS), Tardive Dyskinesia (TD) (a potentially irreversible movement disorder), Ventricular Arrhythmias (including Torsade de pointes, with risk of sudden cardiac death), and severe Agranulocytosis (blood disorder). The risk of Venous Thromboembolism (VTE) is also noted.

Population-specific safety considerations: Labeling states that older patients with dementia-related psychosis treated with this drug class are at an increased risk of death. Newborn infants exposed during the third trimester of pregnancy are at risk for extrapyramidal and/or withdrawal symptoms.

Dose- or exposure-related patterns: Acute Dystonias (muscle spasms) are noted as more likely to occur during treatment initiation or dose increase. Tardive Dyskinesia is associated with long-term exposure.

Safety-related restrictions or limitations: The product is prohibited in the presence of conditions such as circulatory depression, CNS depression, coma, bone marrow depression, and hepatic failure or active hepatic disease, as defined in official labeling.

The regulatory safety summary structures the understanding of the medicine’s risks by explicitly separating frequent, expected adverse events from rare, serious reactions. This framework defines the mandatory safety limitations of the product and highlights specific population vulnerabilities documented in government sources.

Overdose and Emergency Response

Overdose of Proma, a phenothiazine neuroleptic combination, is officially characterized by significant effects on the Central Nervous System and cardiovascular function. Documented clinical manifestations range from somnolence, agitation, and confusion to profound Coma and generalized Seizures (Convulsions). Extrapyramidal Symptoms (EPS), muscle rigidity, and changes in thermoregulation (Hyperpyrexia or Hypothermia) are also officially listed signs of toxicity.

The severe outcomes of overdose are potentially life-threatening. These include severe Hypotension which can lead to Circulatory shock, and serious Cardiac Arrhythmias, notably QT interval prolongation. Regulatory documentation confirms that no specific antidote is known for this overdose.

Immediate medical help must be sought for any suspected overdose. Emergency services must be contacted immediately if the affected person has collapsed, experiences severe respiratory depression, or cannot be awakened. Treatment is officially described as symptomatic and supportive, often requiring procedures like early gastric lavage and continuous monitoring of vital signs and ECG. For managing severe hypotension, certain pressor agents such as Epinephrine are not recommended due to the potential for a paradoxical reduction in blood pressure. Elderly patients are specifically noted to be more susceptible to severe hypotension and neuromuscular reactions in this context.

Therapeutic Uses of Proma

The primary role of this medication is to provide supportive relief and symptomatic management across several distinct therapeutic domains.


Stabilization of Psychotic and Acute Mood Episodes

This medication is commonly used to help manage severe thought disturbances, perceptual changes (like hallucinations or delusions), and significant agitation associated with conditions like schizophrenia and the acute manic phase of bipolar disorder. It helps address symptom clusters that may become intense or disruptive, contributing to improved comfort during periods of heightened symptoms.


Control of Severe Behavioral Crises

The medication is applied in clinical settings that involve acute behavioral crises in children, marked by combativeness and explosive behavior. It supports the patient during difficult episodes by easing distress and assists with maintaining functional stability when symptoms interfere with routine activities.


Relief of Intractable Nausea, Vomiting, and Persistent Spasms

The therapeutic scope also extends to unique non-psychiatric uses, specifically controlling severe, persistent nausea and vomiting, and is used for managing intractable hiccups. The medication is also relevant for easing apprehension and restlessness when short-term symptomatic assistance is needed, such as in certain clinical contexts requiring pre-procedure conditioning. In these scenarios, Proma offers symptomatic relief that helps patients cope more steadily with symptom fluctuations, and may be part of symptomatic management for conditions like acute intermittent porphyria or as an adjunct to the primary treatment for tetanus.

Quick Fact: Relief for Intractable Symptoms
This medication is considered relevant for easing symptoms that are intractable or persistent, particularly for intractable hiccups and severe, persistent emesis (vomiting).

Regulatory References

  1. NIH StatPearls overview

Eligibility and Restrictions for Use

Absolute Contraindications

Proma must not be used by individuals with a known hypersensitivity or allergy to phenothiazines or its components, or by patients who are in a comatose state or exhibiting severe Central Nervous System (CNS) depression. Use is also formally contraindicated for those with Bone Marrow Depression or Circulatory Collapse.

Age-Based Eligibility

The medicine is contraindicated in children less than two years of age due to the risk of respiratory complications. Its safety has not been established for infants under six months of age. Proma is also not approved for the treatment of older adults with dementia-related psychosis.

Physiological and Comorbidity Restrictions

Proma is not recommended for pregnant patients (unless essential, as safety is not established) or for nursing mothers (due to documented excretion in breast milk). Special caution is required for individuals with Cardiovascular Disease, Liver Dysfunction, Renal Failure, a history of Seizure Disorders, or conditions like angle-closure glaucoma or phaeochromocytoma, as stated in official labeling.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Proma's official regulatory documentation defines several interaction patterns with other substances, including strict contraindications and constraints based on pharmacodynamic and pharmacokinetic effects.

Official Contraindicated Combinations

Certain combinations are explicitly prohibited due to the risk of severe outcomes, such as profound Central Nervous System (CNS) depression or cardiac issues. These include:

  • CNS Depressants (Large Amounts): Co-administration with alcohol, narcotics, or barbiturates in large quantities is contraindicated due to the risk of coma and severe CNS depression.
  • QTc-Prolonging Agents: The combination is contraindicated with medicines such as Sotalol, Quinidine, Pimozide, and Procainamide, due to the risk of QTc interval prolongation.
  • Adrenaline (Epinephrine): Adrenaline must not be used to treat hypotension associated with Proma, as the phenothiazine component can reverse its usual effect, leading to a further fall in blood pressure.

Pharmacokinetic and Pharmacodynamic Effects

Interactions are formally documented based on metabolic enzymes and physiological effects:

Mechanism Basis
Exposure Alteration (Pharmacokinetic): CYP enzyme inhibitors (e.g., Fluoxetine, Paroxetine) officially reduce Proma's clearance, leading to increased serum concentrations. Conversely, chronic use of barbiturates can increase clearance and reduce plasma levels.
Therapeutic Antagonism (Pharmacodynamic): Proma may antagonize the therapeutic effects of Antidiabetic Agents and agents used for Parkinson's, such as Levodopa.
Absorption Constraint: Consuming food or taking anticholinergic agents (like certain antiparkinson drugs) may reduce absorption of the oral medicine.

Administration and Population Notes

To prevent reduced absorption, the administration of oral Proma and topical gastrointestinal agents (e.g., antacids) should be separated by more than 2 hours. Furthermore, due to reliance on liver metabolism, caution is noted in patients with hepatic impairment, as dose reduction may be necessary.

Mechanism of Action

Selective Pharmacodynamic Mechanism

Proma operates as a selective, allosteric inhibitor primarily targeting the enzyme Serine/threonine-protein kinase 1 and 2 (MEK1/2). This interaction locks MEK into an inactive conformation, preventing it from performing its enzymatic function: the phosphorylation of its sole known downstream substrates, Extracellular signal-Regulated Kinases (ERK1/2).

This molecular blockade interrupts the signaling sequence known as the MAPK/ERK cascade. The resulting non-activation of ERK1/2 prevents its translocation into the cell nucleus, halting the transcription of genes necessary for cell survival and proliferation. Consequently, this mechanism promotes a shift in the internal cellular balance toward programmed cell death (apoptosis) and reduces the viability of hyperactive cell populations. This inhibitory action is localized to specific intracellular processes and affects only those cells reliant on this particular signaling pathway for their sustained activity.

Dosage and Administration Information

Proma is administered through multiple delivery methods: primarily oral (using tablets or liquid solution) for routine management, and parenterally via deep intramuscular (IM) injection or restricted intravenous (IV) slow infusion for acute needs.

The usage protocol mandates a careful, phased approach. Treatment must be initiated with a low dose that is administered in divided amounts throughout the day. The dosage is then gradually increased (titrated) over defined intervals, such as semi-weekly, until the appropriate response is reached. Once symptoms are controlled, the dose should be systematically reduced to the lowest effective maintenance level. Standard adult maintenance doses typically range from 75 mg to 300 mg daily, though requirements may involve up to 800 mg or more for certain patients.

Special instructions govern both the timing and the route of administration. Oral doses may be taken with or without food; however, antacids must be taken at least 2 hours apart from the medication to prevent impaired absorption. For older or debilitated adults, treatment is typically initiated at one-third to one-half the usual starting dose, with subsequent dose increases occurring more gradually. Parenteral administration requires precise conditions: the solution must be diluted for IV use, must not be given subcutaneously, and the patient should remain recumbent for 30 minutes following the injection.

Recent Clinical Evidence

Research evidence / Overview of Studies for Proma

Evidence for Use in Schizophrenia and Psychotic Disorders

The evidence base for the uses of this medicine is derived from numerous clinical studies, including Randomized Controlled Trials (RCTs) and subsequent Meta-analyses, which compare the compound to both inactive controls (placebo) and other similar medications. The research focused on adult populations experiencing conditions characterized by fluctuating or episodic manifestations, such as schizophrenia.

Studies primarily monitored and measured outcomes related to symptom intensity or variability, including tracking overall changes in mental state and the number of patients who experienced a return of severe symptoms (relapse). Studies reported patterns in the frequency of symptom recurrence (relapse) when compared to placebo groups. Review bodies have noted variability in the quality of the evidence across studies, often due to these dated methodologies. Additionally, research provides limited insight into long-term patient-reported outcomes describing perceived discomfort or improved daily functioning.


Evidence for Acute Agitation and Behavioral Crises

Research has explored short-term symptom changes for acute agitation, primarily involving rapid, short-duration Randomized Controlled Trials and data derived from observational settings evaluating acute care. These studies were conducted during periods of increased symptom activity in patients with psychosis, and research monitored outcomes describing episodic or acute changes. Trials reported measurements of the rapid change in agitation and aggression scales following administration of the medicine. Comparative evidence is lacking against the full range of modern rapid-acting interventions.


Evidence for Non-Psychiatric Uses: Nausea, Vomiting, and Intractable Hiccups

Research conducted on these uses includes older, often non-comparative, controlled trials and small case reports. For nausea and vomiting, studies explored outcomes related to physical discomfort and systemic or functional imbalance. For intractable hiccups, studies monitored outcomes such as the resolution or decrease in the frequency of episodes, with reported findings based primarily on individual case observations. Data for these secondary uses remain insufficient for strong conclusions, and comparative evidence is lacking against some other standard, modern treatment options.


Limitations and Uncertainties in the Research Base

A key limitation is that much of the core evidence for the active ingredients stems from historical studies. The available long-term data are not fully established, as follow-up durations were limited in many early trials. Comparative evidence is lacking in certain areas, and the sample sizes were modest in some research scenarios, meaning research does not determine whether an individual will respond similarly to the group patterns observed.

Key Studies & References

  1. CHLORPROMAZINE HYDROCHLORIDE tablet, sugar coated (DailyMed/FDA Labeling)
  2. Psychosis and schizophrenia in adults: prevention and management (NICE Guideline CG178)

Frequently Asked Questions (FAQ)

Common questions about Proma (FAQ)


Q: How quickly does Proma usually start to work?

A: Studies examining Proma's use for acute agitation have explored rapid changes shortly following administration. For other uses, official protocols describe a process of careful, gradual dose titration, suggesting the desired therapeutic level may be reached over time as the dosage is gradually increased according to the protocol.

Q: Are there any long-term effects of using Proma that have been studied?

A: Official regulatory documents note that Tardive Dyskinesia is associated with long-term exposure. This is a movement disorder that is noted as potentially irreversible. The research base indicates that long-term data for some patient-reported outcomes beyond a certain duration are not fully established.

Q: Does Proma cause weight gain or weight loss?

A: According to official regulatory information, Weight increased is listed as a Very Common adverse reaction, meaning it affects at least 1 out of every 10 people. Weight loss is not listed among the commonly or seriously reported adverse events documented in the product information.

Q: Does using Proma make you feel sleepy or dizzy?

A: Regulatory documentation lists both Sedation and Somnolence (sleepiness) as Very Common adverse reactions. Lightheadedness or dizziness may occur because Orthostatic Hypotension is listed as a Common adverse reaction. Orthostatic Hypotension is a sudden drop in blood pressure when moving from sitting or lying down to standing.

Q: How does Proma compare to older treatments for the same condition?

A: Research has compared this compound to inactive controls (placebo) and to other similar medications within its therapeutic class. Review bodies have noted that comparative evidence may be lacking when assessing Proma against the full range of modern rapid-acting interventions.

Q: Does Proma have a risk of dependence or withdrawal?

A: Official regulatory documentation states that newborn infants exposed to Proma during the third trimester of pregnancy are at risk for withdrawal symptoms. The risk of dependence or withdrawal in the general adult population is not explicitly detailed in the main adverse reaction tables.

Q: What happens if I miss a dose of Proma?

A: Regulatory labels provide specific instructions on what to do if a dose is missed. This information is detailed in the Dosing and Administration section of the official label. Specific regulatory guidance exists for managing a missed dose, which often depends on factors such as the amount of time elapsed.

Q: What should I do if the medicine does not seem to be working?

A: The official usage protocol requires that the dose be gradually increased (titrated) over defined intervals until the appropriate response is reached. If the desired response is not observed, the current dose level is a factor addressed in the established treatment plan.

Q: How does Proma affect blood pressure?

A: Official labeling notes Orthostatic Hypotension (a sudden drop in blood pressure upon standing) as a Common adverse reaction. Due to its potential effect on the circulatory system, the product has formal contraindications regarding the use of Adrenaline to treat associated hypotension.

Q: What is the difference between Proma and a generic version of the drug?

A: Generic versions of a brand-name medicine are required by regulatory agencies to contain the exact same active ingredient(s), be the same strength, and work in the same way. Proma is defined as a combination of two active ingredients.

Q: What type of doctor usually prescribes Proma?

A: Proma is classified as a prescription-only medicine (POM). This means its use must be authorized only by a licensed healthcare provider who has the legal authority to prescribe medication.

Q: Can Proma affect liver function test results?

A: Official labeling states caution is noted in patients with hepatic impairment (liver dysfunction) and dose reduction may be necessary. Hepatic failure and active hepatic disease are listed as formal contraindications. Regulatory labeling addresses these factors as part of the prescribing decision.

Q: What if I vomit shortly after taking Proma?

A: The official labeling provides administration instructions, such as taking oral doses with or without food. In the event that vomiting occurs shortly after taking a dose, regulatory sources indicate that specific guidance from a healthcare provider is necessary in this situation.

Q: Is Proma considered a new or established treatment?

A: Proma is classified as a First-Generation Antipsychotic (FGA), which is also known as a typical neuroleptic. Much of the core evidence base supporting the active ingredients is noted to stem from historical studies, confirming its status as an established treatment.

Q: What age group is Proma generally approved for?

A: The medicine is formally contraindicated in children less than two years of age due to safety concerns. It is also not approved for the treatment of older adults with dementia-related psychosis. The authorized age groups for use are defined by the specific use indication on the product label.

Q: How do I know if I am eligible to be prescribed Proma?

A: Eligibility for Proma is determined by a healthcare provider based on the official product labeling. This includes assessing for absolute contraindications (e.g., CNS depression, coma, bone marrow depression) and specific cautions for those with pre-existing conditions (e.g., Cardiovascular Disease, Liver Dysfunction).

Q: Is it possible to have an allergic reaction to Proma?

A: Yes, official labeling explicitly states that Proma must not be used by individuals with a known hypersensitivity or allergy to phenothiazines or its components. A known hypersensitivity is listed as an Absolute Contraindication.

Q: Can Proma affect my mood or mental health?

A: The general purpose of Proma is to stabilize profound psychological distress and it exerts effects on the Central Nervous System. Regulatory documentation lists Anxiety as a Common adverse reaction.

How should Proma be stored and disposed of?

How to Store and Dispose of Proma?

The storage and disposal requirements for Proma (Chlorpromazine/Promazine) are defined by official regulatory labeling to ensure product stability and safety.

Official Storage Requirements

Proma must be stored at controlled room temperature, strictly protected from light, and kept away from both excess heat and moisture (like the bathroom). The container must be kept tightly closed in its original packaging. Due to the active ingredient's sensitivity, light exposure must be avoided as it can cause the product to visibly darken. The medicine must never be frozen.

Child Safety and Disposal

For safety, Proma must be kept in a secured location, completely out of the sight and reach of children, utilizing a safety cap. When disposing of unused or expired medicine, it must not be flushed down the toilet or poured into drains. Instead, use an authorized drug take-back program or follow specific guidelines to mix the product with an undesirable substance before discarding in household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Proma found in:

A-Z Index: